Reply to comment on ‘An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers’ by Fukui et al.
本文未提供摘要，请点击“查看全文”查看完整内容。